Fount Bio develops glycopolymer-based products utilizing bioorthogonal chemistry to enhance tissue rejuvenation and improve skin health. Their technology addresses the challenge of effectively delivering glycopolymers to target tissues, enabling the creation of crosslinked hyaluronic acid within living tissues.
Funding
$8.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of delivering glycopolymers to target tissues face significant challenges, limiting their effectiveness in tissue rejuvenation and skin health applications. This difficulty hinders the creation of crosslinked hyaluronic acid within living tissues, impacting potential therapeutic outcomes.
Solution
Fount Bio is developing glycopolymer-based products that utilize bioorthogonal chemistry to overcome the challenges of glycopolymer delivery. Their technology enables the creation of crosslinked hyaluronic acid within living tissues, revitalizing tissues and improving skin health. This innovative approach allows for targeted delivery of glycopolymers, enhancing their efficacy in a range of applications. By building crosslinked hyaluronic acid directly within tissues, Fount Bio's platform offers a novel solution for tissue rejuvenation.
Target Audience
The primary target audience includes individuals seeking advanced solutions for tissue rejuvenation and improved skin health, as well as healthcare providers looking for innovative treatment options.
Features
- Glycopolymer-based products for tissue revitalization
- Utilizes bioorthogonal chemistry for targeted delivery
- Enables the creation of crosslinked hyaluronic acid within living tissues